HER2 therapy: molecular mechanisms of trastuzumab resistance.
about
Contribution of CXCL12 secretion to invasion of breast cancer cells.IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Mnk kinase pathway: Cellular functions and biological outcomesAutophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabBreast cancer chemoprevention: old and new approachesNeratinib in HER-2-positive breast cancer: results to date and clinical usefulnessHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerThe somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesComparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopesModulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancerAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Evasion mechanisms to Igf1r inhibition in rhabdomyosarcomaAffibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.A sequence-based survey of the complex structural organization of tumor genomes.Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer.Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEKLapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancerN-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.Evolution of acquired resistance to anti-cancer therapy.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsClinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathwayA multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound.Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.Photochemical internalization of tumor-targeted protein toxins.Gold nanoparticles in breast cancer treatment: promise and potential pitfalls.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsAutomated quantification of aligned collagen for human breast carcinoma prognosis.Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality.Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneFeedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expressionDynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.FOXA1 as a therapeutic target for breast cancer.
P2860
Q22000754-31DFFC4A-D6BE-4C2D-9F80-63F6C2DEA888Q24309891-C4866B23-687E-458F-BD1D-BA6A3478D4E0Q26827810-D6E3F633-7514-48A2-AF08-50C83FE78092Q26865459-AB9B305E-4F00-4E63-9AA3-419F24186B74Q27346475-AE641E1E-442E-48D5-9D32-5AD42C92E1E8Q27693259-0CE44F55-0E4F-43B5-9C2D-4EE58A5C427EQ28071303-66E943AA-112E-4C37-AFF7-B7176836FBBBQ28085413-19EF91AA-FBAC-4B95-B638-6B3FEE599693Q28275430-847E97E5-2414-4E02-A928-0617AB2AE75DQ28542825-524F0908-9C99-4BDB-96F7-8B19DACF7A10Q28729012-F45DAE85-E0A5-497D-A361-56E46446FE9CQ30318240-8676160F-C1A6-4615-B3E1-FA2027EE9D75Q30411769-E0E0BC3F-ADF3-46D4-8BFB-266B0F387D04Q33279445-CB007243-B455-4E23-ABA5-FEA30284576DQ33318574-CFAED819-093B-4BA6-A6EF-8FFA628F4517Q33325344-7656DFE7-E73E-416D-9096-5C385E50B448Q33474183-408EA4BA-37DA-45DB-B0E3-0778E8E19806Q33562476-9FABB847-51C1-42FC-90B0-A8DB59100535Q33579653-8BBBFCF2-7AF1-4E54-AF11-36D151F30426Q33709971-A90DC61D-75C8-490B-8038-BF9CD9F09BAFQ33715830-F2BCF31C-B209-4006-8208-349A1F60596EQ33734993-CEDD1142-9BB2-4A72-A5F6-6E7C338992F7Q33758382-FE51D918-FC02-4D86-A0D9-0F886C90FF48Q33812042-5AF47268-1FA6-4D4A-B56D-03EC648C5846Q33855396-5A4DF960-8651-4B35-A198-3AFF38893FC4Q33880386-69353265-A453-4796-808A-710269FDB4C3Q33914753-E973B9E8-8A45-4795-8D78-D4D995A13BBEQ33976964-B934360F-F62F-4EFA-8DE1-2920172FFA8BQ33989927-6B0884C6-CE06-4F98-9C81-35AA074383AEQ33997021-B970FABD-FBDA-4EE7-A5BD-0E34DC4A16E1Q34068201-B90855C1-99CE-4FF8-ABEA-B0DAE032076FQ34079491-6BB17725-3E8A-4135-80CD-852F417127B0Q34165045-EF34CFC7-1ACC-48B5-A97F-5CA01B18629FQ34210986-DDD495C1-930A-43CE-A9CD-FF3EC63E8998Q34222510-D10985F1-D2D2-45B9-9BD6-9E917D99D4D6Q34241118-CAACA82D-9413-46B1-B630-E32DC7F1BDBAQ34274930-36F52829-E3F4-466C-87C7-2EE479163A21Q34483555-4D2D1C07-9723-437F-911B-27B2A924BE74Q34543685-D3046C5D-CB73-4F39-BB33-21AC9E2014C7Q34610510-D085328D-561E-44C7-805E-AEAD49A03BCE
P2860
HER2 therapy: molecular mechanisms of trastuzumab resistance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@ast
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@en
type
label
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@ast
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@en
prefLabel
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@ast
HER2 therapy: molecular mechanisms of trastuzumab resistance.
@en
P2860
P921
P356
P1476
HER2 therapy: molecular mechanisms of trastuzumab resistance
@en
P2093
Rita Nahta
P2860
P2888
P356
10.1186/BCR1612
P577
2006-01-01T00:00:00Z
P5875
P6179
1043768472